Send us Feedback

Abraxis BioScience (ABII)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW

ABII » Topics » Global Approval Status of ABRAXANE ®

This excerpt taken from the ABII 8-K filed Apr 1, 2008.

Global Approval Status of ABRAXANE®

ABRAXANE is currently approved for marketing in the United States, Canada, India and the European Union. In January 2008, Abraxis received approval from the EU Commission to market ABRAXANE for metastatic breast cancer based on clinical trial data that demonstrated ABRAXANE had significant superiority in the clinical endpoints of response rate, progression free survival and survival when compared with Taxol® in metastatic breast cancer in the second-line setting. ABRAXANE is now approved for commercialization in a total 33 countries.

The company recently announced that its partner, Taiho Pharmaceutical Co., Ltd., has filed a Japanese New Drug Application with the Ministry of Health, Labour and Welfare in Japan to market ABRAXANE for the treatment of breast cancer. The submission in Japan includes four clinical studies that were part of the original New Drug Application in the United States.

 

5

Abraxis BioScience, Inc.

2007 Fourth Quarter/Full Year Financial Results

 

ABRAXANE also is under active review in Australia, Russia, Korea and China by their respective regulatory agencies. The company anticipates approval in Korea and China in the second quarter of 2008, and in Russia and Australia in late 2008.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki